Esperion Therapeutics (ESPR) Tops Q1 EPS by 11c

Esperion Therapeutics (NASDAQ: ESPR) reported Q1 EPS of ($0.93), $0.11 better than the analyst estimate of ($1.04). Revenue for the quarter came in at $18.8 million versus the consensus estimate of $15.39 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• SpaceX receives Baa1 rating from Moody's with stable outlook
• Air France-KLM (AF:FP) (AFLYY) PT Raised to EUR13.50 at UBS